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Summary
 
Recent data indicate that the cell surface glycoprotein CD5 functions as a negative regulator of
T cell receptor (TCR)-mediated signaling. In this study, we examined the regulation of CD5
surface expression during normal thymocyte ontogeny and in mice with developmental and/or
signal transduction defects. The results demonstrate that low level expression of CD5 on
CD4
 
2
 
CD8
 
2
 
 (double negative, DN) thymocytes is independent of TCR gene rearrangement;
however, induction of CD5 surface expression on DN thymocytes requires engagement of the
pre-TCR and is dependent upon the activity of p56
 
lck
 
. At the CD4
 
1
 
CD8
 
1
 
 (double positive,
DP) stage, intermediate CD5 levels are maintained by low affinity TCR–major histocompati-
bility complex (MHC) interactions, and CD5 surface expression is proportional to both the
surface level and signaling capacity of the TCR. High-level expression of CD5 on DP and
CD4
 
1
 
 or CD8
 
1
 
 (single positive, SP) thymocytes is induced by engagement of the 
 
a/b
 
-TCR
by (positively or negatively) selecting ligands. Significantly, CD5 surface expression on mature
SP thymocytes and T cells was found to directly parallel the avidity or signaling intensity of the
positively selecting TCR–MHC-ligand interaction. Taken together, these observations suggest
that the developmental regulation of CD5 in response to TCR signaling and TCR avidity rep-
resents a mechanism for fine tuning of the TCR signaling response.
Key words: CD5 • thymocyte • development • signal transduction
 
C
 
D5 is a monomeric cell surface glycoprotein expressed
on thymocytes, all mature T cells, and a subset of B
cells, B-1 cells (1–4). Putative CD5 ligands include CD72,
a pan-B cell antigen, and CD5L, a recently described pro-
tein expressed on activated splenocytes, B cells, and acti-
vated murine T cell clones (5, 6), suggesting that CD5 may
be involved in regulating immune cell interactions. The
cytoplasmic domain of CD5 contains three potential ty-
rosine phosphorylation sites, including a putative ITAM
(immunoreceptor tyrosine-based activation motif)
 
1
 
 or
ITIM (immunoreceptor tyrosine-based inhibition motif) se-
quence (4, 7) and multiple potential Ser/Thr phosphor-
ylation sites (4). After TCR engagement, CD5 is tyrosine
phosphorylated and becomes associated with a multimolecu-
lar complex that may include TCR-
 
z
 
, CD2, CD4, CD8,
p56
 
lck
 
, p59
 
fyn
 
, PTPC1, and Zap70 (8–12). The physiologi-
cal role of CD5 is still not clearly understood. Previous
studies have shown that treatment of T cells with anti-CD5
enhances TCR-mediated activation, proliferation, and IL-2
production (13–15). On the other hand, more recent data
indicate that CD5 acts to negatively regulate signaling
through both the B and T cell antigen receptors (16, 17).
In the absence of CD5, peritoneal B-1 cells, which nor-
mally are triggered to undergo apoptosis in response to
mIgM cross-linking, develop resistance to apoptosis and
enter the cell cycle (17). Likewise, thymocytes from CD5
 
2/2
 
mice are hyperresponsive to stimulation through the TCR,
and the efficiency of thymocyte selection in CD5
 
2/2
 
, 
 
a/b
 
-
TCR transgenic mice is altered in a manner consistent with
enhanced TCR signaling (16).
CD5 surface expression is tightly regulated throughout T
cell development. Low levels of CD5 are expressed on im-
mature CD4
 
2
 
CD8
 
2
 
 (double negative, DN) thymocytes.
CD5 surface expression then increases at both the
CD4
 
1
 
CD8
 
1
 
 (double positive, DP) and CD4
 
1
 
 or CD8
 
1
 
(single positive, SP) stages and relatively high levels of CD5
are maintained on circulating SP T cells (3, 18). In this
 
1
 
Abbreviations used in this paper:
 
 DN, CD4
 
2
 
CD8
 
2
 
 double negative; DP,
CD4
 
1
 
CD8
 
1
 
 double positive; SP, CD4
 
1
 
 or CD8
 
1
 
 single positive; FCM,
multicolor flow cytometry; ITAM, immunoreceptor tyrosine-based acti-
vation motif.
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study, we sought to identify the cellular mechanisms regu-
lating CD5 expression during development. Our results
demonstrate that CD5 is upregulated at crucial points dur-
ing thymocyte development by pre-TCR and TCR en-
gagement and that the level of CD5 surface expression is
directly related to pre-TCR and TCR signaling intensity.
Significantly, CD5 surface levels were found to vary con-
siderably among mature SP thymocytes and T cells that
express distinct TCRs, and the level of CD5 expression
paralleled the avidity of the positively selecting TCR–MHC-
ligand interaction. Together, these results suggest that the
ability to regulate CD5 surface expression in response to
TCR signaling is important for fine tuning the TCR sig-
naling response and for selection of the mature TCR rep-
ertoire.
 
Materials and Methods
 
Mice
 
C57 BL/6 (B6) mice were bred within our facility. Mutant
strains of mice used for this study included Rag2
 
2/2
 
 (19); MHC
class I
 
2/2
 
 (
 
b
 
2M
 
2/2
 
; reference 20); MHC class II 
 
2/2
 
 (A
 
b
 
2/2
 
; ref-
erence 21); MHC class I 
 
3 
 
II
 
2/2
 
 (
 
b
 
2M
 
2/2
 
 
 
3 
 
A
 
b
 
2/2
 
; reference
22); TCR-
 
a
 
2/2
 
 (23); and lck
 
2/2
 
 (24). 
 
a/b
 
-TCR transgenic lines
included P14 (25), H-Y (26), AND (27), and DO11.10 (DO10;
28). TCR-
 
z
 
 chain transgenic and TCR-
 
z
 
2/2
 
 mice were gener-
ated as previously described (29, 30). For positive selection exper-
iments, mice were bred to C57 BL/6, B10.D2 or B10.A(5R)
mating partners to change the selecting haplotype.
 
Antibodies
 
mAbs used for flow cytometric analysis were purchased from
PharMingen (San Diego, CA) and included fluorochrome-
(FITC or PE) or biotin-conjugated anti-Thy1.2 (53-2.1), anti-
B220 (RA3-6B2), anti-CD4 (H129.19), anti–TCR-
 
b
 
 (H57-
597), anti-CD8
 
a
 
 (53-6.7), anti-CD3
 
e
 
 (145-2C11), anti-CD5
(53-7.3), anti-CD69 (H1.2F3), anti-CD25 (7D4), anti-CD44
(IM7), anti-V
 
a
 
11 (RR8-1), and anti-V
 
a
 
2 (B20.1). Unconju-
gated anti-CD16/CD32 (2.4G2), and rat IgG2a,
 
k
 
 (R35–95)
were used to block nonspecific Fc receptor binding and as control
antibody, respectively. The anti–H-Y clonotypic receptor mAb
(T3.70) and anti-DO10 clonotypic receptor mAb (KJ126) were
purified from cell culture supernatants and labeled with FITC in
our laboratory. Streptavidin Red 670 (GIBCO BRL, Gaithers-
burg, MD) was used in conjunction with biotinylated antibodies
for flow cytometry.
 
Flow Cytometric Analysis
 
Thymi and lymph nodes were excised from mice and single
cell suspensions were prepared. For multicolor flow cytometry
(FCM), thymocytes or lymph node cells were first incubated with
antibody to the Fc receptor (mAb 2.4G2) to prevent nonspecific
binding of antibodies. Background staining was measured using
fluorochrome-conjugated rat IgG2a,
 
k
 
 and designated as control
peaks. For two- and three-color FCM, cells were incubated with
FITC-conjugated, PE-conjugated, and biotinylated antibodies,
followed by the addition of Red 670 streptavidin. FCM was per-
formed on a FACScan
 
Ò
 
 using standard Cell Quest software (Bec-
ton Dickinson, San Jose, CA). Data were collected on 10
 
4
 
 viable
cells as determined by forward and side light scatter. Cell numbers
among the various thymocyte populations were normalized by
gating and collecting on DN, DP, or SP thymocytes. CD5 levels
on thymocyte subpopulations were measured by staining with
CD5, CD4, and CD8 antibodies, followed by a three-color
FACS
 
Ò
 
 analysis and gating according to the CD4/CD8 profile.
 
Purification of DN Thymocyte Populations
 
Total thymocytes from B6 mice were stained with a mixture
of biotinylated anti-CD3, -CD4, -CD8, and -B220 mAb anti-
bodies, washed, and incubated with Streptavidin microbeads
(Miltenyi Biotec, Auburn, CA). DN (CD3
 
2
 
CD4
 
2
 
CD8
 
2
 
B220
 
2
 
)
thymocytes were then purified by magnetic separation accord-
ing to the manufacturer’s protocol (Miltenyi Biotec). Purity of
magnetically separated DN thymocytes was 
 
.
 
95% as assessed
by FCM.
 
Thymocyte Stimulation
 
In Vitro CD3 Cross-linking.
 
24-well plates were coated with
1–50 
 
m
 
g of anti-CD3
 
e
 
 (2C11) in PBS overnight at 4
 
8
 
C and sub-
sequently washed with RPMI 1640 medium (Biofluids Inc.,
Rockville, MD) supplemented with 10% heat-inactivated fetal
bovine serum (Hyclone Labs. Inc., Logan, UT), 0.1 mM MEM
nonessential amino acids, 1 mM MEM sodium pyruvate solution,
1% penicillin/streptavidin, and 5.5 
 
3 
 
10
 
2
 
5
 
 M 2-ME (GIBCO
BRL). 4 
 
3 
 
10
 
6
 
 thymocytes were resuspended in 2 ml of the sup-
plemented RPMI medium and plated in the presence or absence
of 2C11-coated wells for 18 h at 37
 
8
 
C 5% CO
 
2
 
. After cross-link-
ing, thymocytes were spun, washed, and resuspended in FACS
buffer (1
 
3 
 
HBSS, 1% BSA, and 0.1% NaN
 
3
 
) before staining with
antibodies. When required, thymocyte viability was measured by
propidium iodide staining, and data were collected on propidium
iodide–negative cells.
 
In Vivo CD3 Cross-linking.
 
Rag-2
 
2/2
 
 mice were injected in-
traperitoneally with 1–10 
 
m
 
g 2C11 antibody/gram of body wt, or
an equal volume of PBS alone as a control. Mice were killed 1,
3, or 9 d after injection and thymocytes were harvested and stained
as described above.
 
Results
 
CD5 Surface Expression Is Upregulated on DN Thymocytes
by pre-TCR Engagement.
 
Examination of thymocyte sub-
sets from B6 mice reveals a stepwise progression in CD5
surface expression that correlates with thymocyte maturity
(Fig. 1). Low levels of CD5 are expressed on immature
CD4
 
2
 
CD8
 
2
 
 (double negative, DN) thymocytes (CD5
 
lo
 
),
Figure 1. CD5 expression during normal T cell development. (A)
Thymus. (B) Lymph node. Thymocytes and T cells from a C57 BL/6
mouse were stained with CD5, CD4, and CD8, and CD5 was assessed by
gating on the various populations. Histograms represent CD5 expression
on the indicated subpopulations. Dotted lines represent staining with con-
trol (nonspecific) antibody. 
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followed by an approximately sixfold increase in CD5 ex-
pression at the CD4
 
1
 
CD8
 
1
 
 (double positive, DP) stage
(CD5
 
int
 
), and a further three- to fivefold increase in CD5
expression as thymocytes reach the mature CD4
 
1
 
 or CD8
 
1
 
(single positive, SP) stage (CD5
 
hi
 
). Relatively high levels of
CD5 are maintained on mature peripheral SP T cells (Fig.
1), with the highest expression on CD4
 
1
 
 T cells (Fig. 1).
To investigate how CD5 expression is controlled during
development, we began by examining thymocytes from
mutant strains of mice that exhibit defects in T cell devel-
opment, signal transduction, or both.
Thymocytes from mice deficient in expression of the
Rag-2 gene product (Rag-2
 
2/2
 
) fail to develop beyond the
DN stage and fail to express either pre-TCR or 
 
a/b
 
-TCR
surface complexes owing to a defect in the initiation of
V-(D)-J recombination (19, 31). Yet thymocytes from
Rag-2
 
2/2
 
 mice express low levels of CD5 (Fig. 2). CD5
expression was also observed on TCR
 
2
 
 DN thymocytes
from TCR-
 
b
 
2/2
 
 mice (results not shown) demonstrating
that neither the pre-TCR nor the 
 
a/b
 
-TCR is required for
low-level expression of CD5. DN thymocytes from mice in
which TCR-
 
a
 
 rearrangement is inhibited (TCR-
 
a
 
2/2
 
)
mature to the DP stage, but are unable to progress further in
development (23). Significantly, DP thymocytes from
TCR-
 
a
 
2/2
 
 mice express higher levels of CD5 than do DN
thymocytes (Fig. 2). In fact, CD5 levels on the majority of DP
thymocytes from control (TCR-
 
a1/1) and TCR-a2/2 mice
are similar, differing mainly in the absence of a small CD5hi
DP population in TCR-a2/2 mice (Fig. 2; reference 32).
Since in the absence of TCR-a chain, thymocytes can
express pre-TCR but not a/b-TCR complexes, we next
investigated whether pre-TCR signals could upregulate
CD5 surface expression. Expression of the pre-TCR begins
at the DN CD44lo/2 CD251 stage of development and is
required for transition to the DN CD442CD252 stage (33,
34). Examination of DN CD442CD252 thymocytes re-
vealed that these cells express three- to fourfold higher lev-
els of surface CD5 than do their immediate precursors, DN
CD44lo/2 CD251 thymocytes (Fig. 3 A). Signals trans-
duced by the pre-TCR induce cell cycle progression, re-
sulting in the expansion of cells that have undergone pro-
ductive b-rearrangement, a process termed “b selection”
(34). Consequently, in normal mice, the DN CD44lo/2
CD251 thymocyte compartment consists of two subsets
(“E” and “L”) that can be distinguished on the basis of cell
size (34). The E subset contains small resting cells that ei-
ther have not yet undergone b selection or have failed to
productively rearrange their b chain genes, whereas the L
subset consists of larger cells that have received pre-TCR
signals and have entered the cell cycle (reference 34; Fig.
3  A). Examination of CD5 surface expression on DN
CD44lo/2 CD251 thymocyte subsets revealed that L cells
express approximately fourfold higher levels of CD5 than
do E cells (Fig. 3 A). Collectively, these results indicate that
signaling through the pre-TCR upregulates CD5 surface
expression on DN thymocytes. To test this hypothesis fur-
ther, we next determined the effect of CD3 cross-linking
on CD5 expression. Injection of anti-CD3 antibodies into
Rag-22/2 mice has been shown to mimic pre-TCR signal-
ing as it promotes the formation of DP thymocytes (35,
36). This response has been attributed to the low level ex-
pression of CD3 signaling subunits on the surface of Rag-
22/2 thymocytes in the absence of b and pre-Ta chains
(37). To ascertain whether direct engagement of these sur-
face complexes could induce CD5 expression on DN thy-
mocytes before their transition to the DP stage, Rag-22/2
mice were analyzed at multiple time points after intraperi-
toneal injection of anti-CD3 antibody. Significantly, as
early as 24 h after anti-CD3 injection, thymocyte cellular-
ity was increased fourfold and Rag-22/2 thymocytes,
which still consisted entirely of DN cells, expressed high
levels of CD5 (Fig. 3 B). Induction of the early activation
antigen, CD69, was also observed on DN thymocytes 24 h
after injection (Fig. 3 B). At 3 d after injection, CD5 levels
on DN thymocytes remained high and large numbers of
CD5int–hi DP thymocytes were present in the thymus of
Rag-22/2 mice (data not shown).
Because signaling by the pre-TCR has been shown to be
dependent upon the activity of the protein tyrosine kinase
p56lck (24, 38), we also examined the importance of Lck for
the induction of CD5 expression. DN, CD44lo/2CD251
thymocytes from lck2/2 mice were found to express lower
levels of CD5 than DN, CD44lo/2CD251 thymocytes from
lck1/1 mice (Fig. 3 C). In addition, although lck2/2 mice
contained a/b-TCR1 DP thymocytes, these cells also ex-
pressed low levels of CD5 relative to DP thymocytes from
lck1/1 mice (Fig. 3 C).
To determine if induction of CD5 on DN thymocytes
correlates with pre-TCR signal intensity, Rag-22/2 mice
were injected with varying amounts of stimulating (anti-
CD3e) antibody. The results demonstrated a direct rela-
tionship between anti-CD3e dosage and CD5 surface ex-
pression (Fig. 3 B). The relationship between pre-TCR
signaling capacity and CD5 expression was also examined
Figure 2. CD5 surface expression on thymocytes from Rag-22/2 and
TCR-a2/2 mice. Dot plots illustrate the CD4/CD8 staining profile and
demonstrate the stage at which thymocyte development is blocked. His-
tograms depict CD5 and CD3 surface levels on gated CD42CD82 (DN)
thymocytes (A), or CD41CD81 (DP) thymocytes (B). CD5 and CD3
surface expression on DN and DP thymocytes from control (WT) animals
are included for comparison. Dotted lines represent control peaks.2304 Regulation of CD5 Expression during T Cell Development
by analyzing CD5 expression on DP thymocytes from
TCR-a2/2 3 z2/2 mice, which express pre-TCR in the
absence of associated z chain. Previous work has shown
that the pre-TCR is expressed and can function, though
less efficiently, in the absence of z to promote the forma-
tion of DP thymocytes, indicating that z chain contributes
quantitatively to the pre-TCR signaling response (29, 38).
Indeed, DP thymocytes from TCR-a2/2 3 z2/2 mice ex-
pressed significantly lower levels of CD5 than did DP thy-
mocytes from TCR-a2/2 mice (Fig. 3 D). Taken together,
these results demonstrate that signals transduced by the pre-
TCR induce the upregulation of CD5 on DN thymocytes,
resulting in the formation of DP CD5int thymocytes.
CD5 Expression on DP Thymocytes Is Maintained by a/b-
TCR Engagement and Is Proportional to TCR Surface Levels and
TCR Signaling Capacity. CD5 surface expression has been
shown previously to correlate with expression of the a/b-
TCR during T cell development (3, 18). To investigate
this relationship further, we used mice generated previously
that express different levels of TCR due to variable expres-
sion of z chain (30). Examination of DP thymocytes from
z1/2 and z1/1; z tg mice, which express low or high levels
of a/b-TCR relative to z1/1 mice, respectively, revealed a
direct relationship between TCR surface expression and
mean CD5 surface expression on DP thymocytes (Fig. 4 A).
To determine if TCR engagement was specifically re-
quired for CD5 expression on DP thymocytes, we then ex-
amined thymocytes from mice lacking MHC (class I 3
II)2/2 in which development is arrested at the TCR1 DP
stage. Although most DP thymocytes from MHC class (I 3
II)2/2 mice express higher levels of a/b-TCR than do DP
thymocytes from control mice, these cells express low lev-
Figure 3. (A) CD5 surface expression on
CD42CD82 (DN) thymocyte subsets. DN
thymocytes from B6 mice were isolated as
described in Materials and Methods, and
stained with CD25 and CD44 antibodies to
distinguish the various DN subpopulations
(dot plot). Histogram on the left shows
CD5 expression levels on gated CD442
CD251 and CD442CD252 thymocyte sub-
populations. The middle histogram shows
forward scatter profile of DN CD442
CD251 thymocytes from B6 mice (white
histogram) or from Rag-22/2 mice (gray histo-
gram). Rag-22/2 thymocytes were used for
placement of E and L gates as shown. Right
histogram shows CD5 expression on E and
L gated DN CD442CD251 thymocytes
from B6 mice. (B) Induction of CD5 and
CD69 surface expression on Rag-22/2 DN
thymocytes by anti-CD3e antibody. Left
and middle: 200 mg of anti-CD3e ( 2C11)
antibody was injected into Rag-22/2 mice
(12C11) and CD5 (left) or CD69 (middle)
surface levels on DN thymocytes were de-
termined 24 h later. Control animals were
injected with PBS (22C11). Right: Rag-22/2
mice were injected with 0, 1, or 10 mg 2C11/gram body wt and DN thymocytes were analyzed for CD5 surface expression 3 d later. (C) CD5 surface
expression on DN CD251 and CD41CD81 (DP) thymocytes from lck2/2 mice. CD5 levels on DN CD251 and DP thymocytes from control (lck1/1)
mice are included for comparison. (D) CD5 surface expression on gated CD41CD81 (DP) thymocytes from TCR-a2/2 and TCR-a2/2 3 z2/2 mice.
Dotted lines represent staining with control antibody.
Figure 4. TCR levels and TCR signaling intensity influence CD5 ex-
pression on CD41CD81 (DP) thymocytes. (A) Effect of TCR levels on
CD5 expression. Histograms depict CD5 and CD3 expression on gated
CD41CD81 (DP) thymocytes from TCR-z heterozygotes (TCR-z1/2)
and TCR-z-transgenic mice (TCR-z1/1; z tg) relative to control mice
(TCR-z1/1). (B) Relationship between TCR signal intensity and CD5
expression. DP thymocytes were stimulated for 18 h on plates coated
with the indicated amount of cross-linking antibody (anti-CD3e; mAb
2C11) then analyzed for CD5 surface expression. (C) Effect of TCR sig-
naling capacity on CD5 expression. Histograms depict CD5 and CD3
surface expression on DP thymocytes from TCR-z2/2 mice reconstituted
with transgenes encoding either full length z chain (z-3 ITAM) or z chain
lacking sequences required for signal transduction (z-0 ITAM) (reference
30, see Results). Dotted lines represent staining with control antibody.2305 Azzam et al.
els of CD5 (Fig. 5 A). Indeed, the level of CD5 expressed
on DP thymocytes from MHC class (I 3 II)2/2 mice is
similar to that expressed on DN thymocytes (Fig. 5 B). In
contrast, DP thymocytes from mice lacking expression of
either MHC class I (Fig. 5, A and B) or MHC class II alone
(data not shown) express normal (intermediate) levels of
CD5. Thus, interaction of TCR1 DP thymocytes with
self-MHC appears to be required to sustain CD5 surface
expression at levels above those observed on DN thymo-
cytes. Consistent with this idea, anti-TCR cross-linking
resulted in induction of both CD5 and CD69 on DP
thymocytes from class (I 3 II)2/2 mice to levels comparable
to those observed on DP thymocytes from control mice
(Fig. 5 C).
The relationship between TCR signal intensity and
CD5 expression on DP thymocytes was examined by in
vitro cross-linking with varying amounts of anti-CD3e.
The results of this experiment revealed a direct relationship
between the concentration of cross-linking antibody and
CD5 surface levels (Fig. 4 B). The correlation between
TCR signaling and CD5 induction could also be assessed
using transgenic mice that express similar levels of TCR
but whose TCRs differ in their signaling potential due to
differences in the total number of ITAMs contained within
the z chain (30). z2/2 mice that have been reconstituted
with a transgene encoding the full-length z chain (z-3
ITAM) express surface TCRs that contain a full comple-
ment of ITAMs (10 ITAMs per TCR complex), whereas
reconstitution of z2/2 mice with a truncated z chain trans-
gene lacking all three ITAMS (z-0 ITAM) results in surface
expression of TCRs that contain only four ITAMs per
TCR complex (provided by the CD3 chains) (30). Al-
though the TCR levels on DP thymocytes from these
transgenic mice are nearly identical, mean CD5 levels are
significantly lower on the majority of DP thymocytes from
z-0 ITAM mice relative to the z-3 ITAM mice (Fig. 4 B).
Thus, the level of TCR surface expression and the intensity
of the TCR signal quantitatively influence CD5 surface ex-
pression on DP thymocytes.
CD5 Levels on SP Thymocytes and T Cells Are Dictated by
the Avidity of the Positively Selecting TCR Interaction. The
observation that CD5 is upregulated to high levels on DP
thymocytes in vivo after engagement of the TCR by
ligands that promote either positive or negative selection,
or in vitro by cross-linking of the TCR (references 32, 39–
42; Fig. 4) suggested the possibility that CD5 surface ex-
pression might be quantitatively influenced by the affinity
of the TCR for selecting ligand, together with the concen-
tration of selecting ligand (TCR avidity). To address this
question, we analyzed CD5 surface expression on thy-
mocytes from two different MHC class I–restricted (H-Y,
reference 26, and P14, reference 25) and two different
MHC class II–restricted (DO10, reference 28, and AND,
reference 27) TCR transgenic lines, each expressing dis-
tinct clonotypic TCRs. Under conditions known to pro-
mote positive selection, CD5 levels on DP thymocytes
from all of the transgenic mice were higher than those ex-
pressed on the majority of DP thymocytes from nontrans-
genic mice (Fig. 6, A and B). As the shift in CD5 surface
expression from CD5int to CD5hi on the bulk of DP thy-
mocytes in transgenic mice is observed in either positively
or negatively selecting but not in nonselecting backgrounds
(data not shown), this result presumably reflects the fact
that most DP thymocytes in TCR transgenic mice, but
only a small percentage of DP thymocytes from non-TCR
transgenic mice express TCRs that are engaged by selecting
ligand (Fig. 6, A and B). However, gating on transgenic
TCRhi SP thymocytes revealed clear differences in the
level of CD5 expression among the various transgenic lines,
with P14 . H-Y on CD8 SP thymocytes for the MHC
class I–restricted TCRs, and AND . DO10 on the CD4
SP thymocytes for the MHC class II–restricted TCRs (Fig.
6, A and B). Significantly, the relative differences in CD5
surface expression were maintained on peripheral SP T
cells generated by positive selection (CD81 T cells in the
case of P14 and H-Y TCR transgenic mice, and CD41 T
Figure 5. CD5 surface expression on thymocytes from mice lacking
MHC. (A) Histograms show CD5 and CD3 surface levels on gated
CD41CD81 (DP) thymocyte populations from mice lacking expression of
MHC class I (MHC I2/2) or MHC class I and class II [MHC (I 3 II2/2)].
CD3 and CD5 levels on DP thymocytes from control B6 (WT) mice are
included for comparison. (B) CD5 levels on CD42CD82 (DN) and DP
thymocytes from MHC I2/2 and MHC (I 3 II)2/2 mice. (C) Induction
of CD5 by CD3 cross-linking. Thymocytes from C56 BL/6 (WT) and
MHC (I 3 II)2/2 mice were incubated in the presence (12C11) or ab-
sence (22C11) of plate-bound anti-CD3e antibody (50 mg) for 18 h at
378C and CD5 and CD69 expression on DP thymocytes was assessed by
FACSÒ. Dotted lines represent staining with control antibodies.2306 Regulation of CD5 Expression during T Cell Development
cells in the case of AND and DO10 TCR transgenic mice;
Fig. 6, A and B). Since TCR levels on SP T cells from the
class I– or class II–restricted TCR transgenic mice were
similar as assessed by staining with anti-CD3e or anti–
TCR-b antibodies (data not shown), these results sug-
gested that the differences in CD5 levels might reflect dif-
ferences in the avidity of the positive selecting interaction
(i.e., P14 . H-Y and AND . DO10). Although the na-
tural positively selecting ligands for these TCRs are un-
known, their relative avidity can be inferred by the effi-
ciency of positive selection (43). Experimental data support
the idea that within the “window” of TCR–ligand-MHC
Figure 6. CD5 expression on thymocytes and mature T cells from TCR transgenic mice. (A) Comparison of CD5 levels on thymocytes and lymph
node T cells from MHC class I–restricted (P14 H-2b and H-Y H-2b) TCR transgenic mice. (B) Comparison of CD5 levels on thymocytes and lymph
node T cells from MHC class II–restricted (AND H-2bxk and DO10 H-2d) TCR transgenic mice. Single-color histograms represent CD5 staining on
CD41CD81 thymocytes, as well as on CD81 SP thymocytes and T cells (HY and P14 TCR transgenic mice), or CD41 SP thymocytes and T cells
(AND and DO10 TCR transgenic mice). Shown are CD5 levels on transgenic TCRhi gated cells. Data obtained for similar cell populations from non-
transgenic (WT) mice are shown for comparison. Numbers in boxes depict mean CD5 fluorescence for the transgenic TCRhi cells.2307 Azzam et al.
interactions that promote positive selection, higher avidity
interactions increase the efficiency of positive selection, re-
sulting in the generation of increased numbers of TCRhi SP
thymocytes (43). In the case of the H-Y and P14 transgenic
TCRs, several observations indicate that the efficiency of
positive selection is greater in P14 than in H-Y (female)
TCR transgenic mice (25, 26). For example, both the total
number of transgenic TCRhi thymocytes and the number
of transgenic TCRhiCD81 thymocytes and T cells in P14
TCR transgenic mice exceeds that observed in H-Y trans-
genic female mice (Fig. 6 A). These observations suggest,
although by no means prove, that positive selection is me-
diated by higher avidity TCR–ligand-MHC interactions in
P14 transgenic mice than in H-Y (female) transgenic mice.
Applying similar criteria, positive selection also appears to
be mediated by a higher avidity TCR–ligand-MHC inter-
action in AND transgenic mice than in DO10 transgenic
mice (Fig. 6 B).
To further investigate the possible relationship between
CD5 expression and TCR avidity, we analyzed positive se-
lection in the same transgenic line (DO10) under condi-
tions that have been shown to alter the avidity of the posi-
tively selecting TCR–MHC-ligand interaction (44, 45).
Thymocytes with DO10 TCR are positively selected in
both the H-2d and H-2b backgrounds; however, the small
thymus size and reduction in DP thymocytes observed in
DO10, H-2b mice is consistent with the induction of par-
tial clonal deletion as a result of increased TCR–MHC-
ligand avidity interactions (44, 45). Significantly, the CD41
transgenic TCRhi (KJ-126hi) thymocytes and T cells gener-
ated in DO10 H-2bxd mice were found to express higher
surface levels of CD5 than do CD41 KJ-126hi thymocytes
and T cells from DO10 H-2dxd mice (Fig. 7 A). Notably,
the KJ-126hiCD41 T cells from DO10 H-2bxd and DO10
H-2dxd express similar levels of a/b-TCR and CD4 (Fig.
7 A). Thus, the difference in CD5 levels could not be at-
tributed to differences in TCR or CD4 coreceptor surface
expression. In addition, since the identical transgenic TCR
was used in these experiments, the differences observed
could not reflect variation in the timing or onset of trans-
gene expression during thymocyte development. Rather,
these results suggest that the level of CD5 expression on
mature T cells is determined during development in the
thymus by the avidity of the TCR for selecting ligand.
A prediction of this hypothesis is that the avidity of the
positively selecting TCR–MHC-ligand interaction may
regulate the level of CD5 surface expression by influencing
the intensity of the TCR signaling response. To examine
this relationship, we analyzed the effect on CD5 expression
produced by lowering the TCR signaling potential from
10 to 4 ITAMs per TCR complex. For these experiments,
we chose the P14 TCR transgene because prior experi-
ments had revealed that significant numbers of P14 TCRhi
(Va2hi) CD8 SP T cells are generated in both z-3 ITAM
and z-0 ITAM P14-TCR transgenic mice (Fig. 7 B). We
found that lowering the TCR signaling capacity by re-
moval of z chain ITAMs (z-0 ITAM tg versus z-3 ITAM
tg) resulted in the generation of Va2hi CD8-SP cells that
express lower levels of CD5 (Fig. 7 B). Taken together,
these results indicate that CD5 surface expression is devel-
opmentally regulated in response to the avidity of the TCR
for positively selecting ligands.
Discussion
Interest in the role of CD5 in lymphocyte development
has grown considerably in light of recent data suggesting
that CD5 functions to negatively regulate signaling through
the B and T cell antigen receptors (16, 17). In this study,
we examined CD5 expression during normal thymocyte
development and in mice with defects in thymocyte matu-
ration. Our results demonstrate a critical role for pre-TCR
and TCR signals, and notably TCR avidity, in regulating
CD5 surface expression.
Early DN thymocytes express very low levels of CD5
independent of their ability to undergo TCR gene rear-
rangement, and therefore independent of their ability to
express pre-TCR and/or TCR complexes. That the pre-
TCR is not required for initial CD5 expression on early
DN thymocytes is not surprising, as previous studies have
documented very low levels of CD5 on pro-T cells in the
thymus (46). Of significance, however, is that signals trans-
duced by the pre-TCR upregulate CD5, and that the level
of CD5 surface expression reflects the extent or intensity of
pre-TCR signaling (Fig. 3 B; reference 47). Consistent
with this observation, both p56lck and z chain, which ap-
pear to act primarily by quantitatively influencing the pre-
TCR signaling response (24, 29, 38, 47, 48), are required
for full CD5 induction by the pre-TCR (29, 49; Fig. 3 C).
Although these results suggest a possible role for CD5 at
the DN–DP transition, perhaps through modulation of
pre-TCR signaling threshold, the fact that thymocyte mat-
uration appears unaffected in CD52/2 mice argues that this
function is not critical for T cell development (50).
Interestingly, most DP thymocytes from TCR-a2/2
mice (which can express pre-TCR complexes but are a/b-
TCR2) express nearly normal (intermediate) levels of
CD5, whereas CD5 levels on DP thymocytes from MHC
(class I 3 II)2/2 mice (which are a/b-TCRint–hi) express
low levels of CD5. We interpret these observations as indi-
cating that continued signaling, either through the pre-
TCR or a/b-TCR, is required to maintain CD5 expres-
sion at intermediate levels on DP thymocytes. Thus in
TCR-a2/2 mice, continued expression of the pre-TCR
provides this signaling function, whereas in MHC (class I 3
II)2/2 mice, replacement of the pre-TCR by TCR com-
plexes that are incapable of generating signals by interacting
with MHC leads to the downregulation of CD5. Results
consistent with our own have also been reported by Dutz
et al., who noted a specific requirement for MHC class I
for the generation of CD5int DP thymocytes in class
I–restricted H-Y TCR transgenic mice (51). The observa-
tion that most DP thymocytes from transgenic mice express
intermediate levels of CD5 in a nonselecting background
(51) further indicates that extremely low avidity or “non-
cognate” TCR–MHC interactions are sufficient to main-2308 Regulation of CD5 Expression during T Cell Development
Figure 7. (A) Comparison of CD5 levels on CD41 thymocytes and T cells from DO10 TCR transgenic mice generated in the H-2dxd and H-2bxd
backgrounds. Top: Two-color (CD4 versus CD8) analysis of thymocytes from DO10/H-2dxd and DO10/H-2bxd mice. Histogram depicts CD5 levels on
CD41 KJ126hi thymocytes. Bottom: Two-color (CD4 versus KJ126) analysis of lymph node cells from DO10/H-2dxd and DO10/H-2bxd mice. Large his-
togram depicts CD5 levels on CD41 KJ126hi T cells. Small histograms show CD4 and KJ126-TCR levels on total CD41 T cells. Numbers in boxes de-
pict mean CD5 fluorescence for the transgenic TCRhi cells. (B) Comparison of CD5 levels on CD81 T cells generated in P14 TCR transgenic mice
expressing TCRs containing full-length (z-3 ITAM) or signaling defective (z-0 ITAM) z-chains Histograms depict Va2, TCR-b, CD8, or CD5 staining
on gated CD81Va21 T cells (gates are shown in the two-color plots). Numbers in boxes depict mean CD5 fluorescence.2309 Azzam et al.
tain intermediate levels of CD5 expression on DP thy-
mocytes.
CD5 is upregulated to high levels on a small subset of
DP thymocytes, before TCR upregulation or CD4 /CD8
lineage commitment as assessed by coreceptor downregula-
tion (32, 39–41, 51). Data from our own and previous
work indicate that this response is mediated by higher avid-
ity TCR–MHC-ligand interactions than those that are re-
quired to maintain intermediate levels of CD5 expression
on DP thymocytes (32, 39–41, 51). In agreement with this
model, CD5hi DP thymocytes are absent both in TCR-a2/2
mice that lack a/b-TCR and in MHC (class I 3 II)2/2
mice that express a/b-TCR but are incapable of engaging
ligand. Conversely, in TCR transgenic mice in which a
defined TCR is expressed on a high percentage of DP thy-
mocytes, a large cohort of CD5hi DP thymocytes is gener-
ated under conditions that promote either positive or nega-
tive selection but not in a nonselecting background (51).
Thus, only those DP thymocytes that express TCRs that
can interact with MHC-ligand with sufficiently high affin-
ity to promote either positive or negative selection upregu-
late CD5 surface expression to high levels.
Although CD5 upregulation on DP thymocytes upon
TCR engagement has been previously shown, the current
study reveals that CD5 surface expression on SP thy-
mocytes and T cells differs depending upon the clonotypic
TCR that they express. Transgenic TCRhi SP T cells were
found to express similar (P14), lower (H-Y, AND,
D011.10/H-2d), or higher (D011.10/H-2bxd) levels of CD5
compared with mean CD5 expression on corresponding SP
T cell populations from nontransgenic mice (Figs. 6 and 7).
Our data also suggest that the level of CD5 expressed on
SP thymocytes and T cells generated during positive selec-
tion corresponds to the avidity (signal intensity) of the pos-
itively selecting TCR–MHC-ligand interaction. When the
avidity of the positively selecting TCR–MHC-ligand in-
teraction was varied for the same TCR by changing the
MHC haplotype or the signal intensity was varied by re-
moval of TCR ITAMs, the results also supported this hy-
pothesis. Because the antigen specificity of the transgenic
TCRs used in this study should result in the generation of
“naive” SP thymocytes and T cells that should not encoun-
ter their native antigen in vivo, our results also argue that
CD5 levels are “fixed” during positive selection on the ba-
sis of TCR specificity and these relative levels are subse-
quently maintained on circulating mature SP T cells inde-
pendent of engagement of the TCR by antigen. The
mechanism by which CD5 expression levels are established
during thymocyte development could involve modulation
of CD5 in response to TCR signal intensity followed by
maintenance of this relative level of expression on mature
T cells. Alternatively, it is possible that only those thy-
mocytes that constitutively express the appropriate level of
CD5 with respect to their clonotypic TCR are selected to
mature to the SP stage. Since these mechanisms are not
mutually exclusive, both may also be operative.
Since CD5 acts to attenuate signaling by the TCR (16),
the capacity of cells to regulate CD5 surface levels could
serve several important functions during development. For
example, induction of CD5 on thymocytes and mature T
cells after TCR engagement may serve to dampen the
TCR signaling response, especially after restimulation. At
the DP stage, upregulation of CD5 represents an early re-
sponse to engagement of the TCR by selecting ligand as it
precedes upregulation of the TCR (32, 40, 51). The rapid
increase in CD5 levels after initial TCR engagement may
act to inhibit subsequent TCR-mediated signaling re-
sponses. Increased CD5 expression in response to TCR en-
gagement could also provide an off signal that participates
in terminating the activation response. Another role sug-
gested by our data is that CD5 levels may influence the
triggering threshold for T cell activation. This function
might be particularly important during thymocyte selection
when the TCR signaling response dictates the fate of DP
thymocytes (i.e., either positive or negative selection). In-
deed, analysis of CD5-deficient mice has shown that CD5
does participate in thymocyte selection through its ability
to negatively regulate the TCR signaling response (16). In-
terestingly, the effect of CD5 deletion on thymocyte selec-
tion varied among different TCR transgenic mice, result-
ing in enhanced positive selection in H-Y TCR transgenic
mice and a shift from positive selection to partial negative
selection in P14 TCR transgenic mice (16).
The ability of thymocytes to regulate CD5 surface ex-
pression also suggests that the relative impact of CD5 on
TCR signal transduction can be varied in relation to the
avidity of the TCR for selecting ligand, providing a mecha-
nism for fine tuning of the TCR signaling response. Surface
levels of both CD4 and CD8, which unlike CD5 provide
costimulatory signals, also have been shown to vary among
individual SP T cells that express distinct TCRs (52). An
advantage of using multiple surface structures such as CD4,
CD8, and CD5 to influence the overall signaling response
delivered to thymocytes and T cells could be to enable a
much broader range of TCRs to transduce signals appropri-
ate for positive selection than would otherwise be possible if
the affinity of the TCR for selecting ligand alone dictated
the outcome. Thus, the potential for TCR signal modula-
tion by CD5 may be particularly useful for generating the
maximum possible diversity in the mature T cell repertoire.
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